Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Asaretoclax

Small molecule · Inhibitor of B-cell lymphoma 2 (Bcl-2) (BCL2) · developed by K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals

Phase 1/2 Most advanced trial (none active)
ZNTL Developer
1 Registered trials

What is Asaretoclax?

Asaretoclax is an orally bioavailable inhibitor of the anti-apoptotic protein Bcl-2. It binds Bcl-2 and inhibits its activity, restoring apoptotic processes in cells that overexpress it. It is being studied in AL amyloidosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
ZN-d5
Drug type
Small molecule
Targets
B-cell lymphoma 2 (Bcl-2) (BCL2)
Mechanism
Inhibitor of B-cell lymphoma 2 (Bcl-2) (BCL2)
Pathways
apoptosis
Therapy area
Oncology
Developer
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. (ZNTL)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
GY6FD5FXA3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05199337 Phase 1/2 Amyloidosis Completed ZNTL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

AL AmyloidosisAmyloidosis

Other drugs acting on BCL2

More from K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the ZNTL page.

Follow ZNTL, the company behind Asaretoclax

See ZNTL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ZNTL catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.